Month: May 2019





Biotech
One Hot Stock
TradersPro Alerts

Generex Biotechnology Corporation (GNBT) Buy Target 1.40 – Sell Target 2 $2.85

Generex Biotechnology Corporation, through its subsidiaries, primarily engages in the administration of formulations of large molecule drugs to the oral cavity using a hand-held aerosol applicator in Canada and the United States. It offers Generex Oral-lyn, an insulin formulation administered as a fine spray into the oral cavity. The company is also developing AE37, a […]

Read More
Marijuana
Stock Picks

2 Billionaires Just Bought This Top Marijuana Stock – Should You?

These 2 billionaire investors are bullish on this major cannabis stock. Here’s why.

Read More
China
Fibonacci Retracement
Fundamental Analysis
InvestivDaily
Risk
Semiconductor
Tariffs
Tech Industry
Technical Analysis
Technology
Trade War
Value Investing

Beaten, but not broken: don’t ignore INTC’s value proposition

If you read my highlights in this space on a regular basis, you’ve seen me highlight a number of stocks in the semiconductor industry. It’s an interesting segment of the market to me for a number of different reasons. Over the last decade-plus, it’s been one of the highest-performing pockets of the market, arguably one […]

Read More
China
Consumer Staples
Fibonacci Retracement
Fundamental Analysis
InvestivDaily
Risk
Tariffs
Technical Analysis
Trade War
Value Investing
Value Traps

Should ADM be part of a smart defensive strategy?

It really seems like the market is going to take any queues for the foreseeable future from the U.S.-China trade front. With both sides seemingly digging in on hard-line positions that they don’t want to be moved off of, it looks like uncertainty is going to continue to rule the markets as we move into […]

Read More
Health
Pharmaceuticals

Why Johnson & Johnson Is Down More than 6% in the Last Week

Shares of Johnson & Johnson (JNJ) continued lower during Wednesday’s session due to a highly publicized trial against the multinational company in the state of Oklahoma. Investors have been skittish over the lead-up to the trial and its massive implications regarding the nationwide opioid crisis, scaring them into dragging the stock down to its lowest […]

Read More